Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

- Second proof-of-concept study in cognition started with Alzheimer/pain candidate EVT 101; start of Phase II neuropathic pain study delayed until mid 2008 following IND review

- Phase I studies for EVT 302 (smoking cessation) progressing as planned; there were no significant adverse effect findings so far; further Phase I study started to confirm superiority of the compound (no liability with tyramine containing foods)

- Disposal of Chemical Development Business to Aptuit for GBP31.5 million, effective November 2007

- Proposed acquisition of US-based Biotech company Renovis and anticipated NASDAQ listing; expected to close in Q1 2008

- Public-private-partnership "European Screening Port" established in Hamburg together with the City of Hamburg and the State of Germany

"The third quarter was a major one for Evotec. The sale of our Chemical Development Business to Aptuit and the proposed acquisition of Renovis are major milestones in the implementation of our strategic plan to transition into a drug discovery and development company for Central Nervous Systems (CNS) diseases. These transactions significantly strengthen our liquidity and accelerate our CNS pipeline development. Renovis adds complementary pipeline projects to our R&D portfolio and sufficient cash to fund their future development. Three Renovis programs in pain and inflammatory disease are expected to enter Phase I clinical trials in 2008/2009", said Jorn Aldag, President & Chief Executive Officer of Evotec AG. "In October, we also released compelling, top-line, proof-of-concept data in elderly insomnia patients for our lead compound EVT 201. These confirmed earlier data from adult insomniacs demonstrating desirable advantages in sleep onset, maintenance, and lack of hangover. We expect the compound to be attractive to potential partners as it addresses key limitations of competitive therapies. We aim to out-license EVT 201 in 2008."

2007 Financial Targets Conf
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: IPXL).  Such investors are advised to contact ... 888-476-6529, ext. 237. The investigation concerns whether ... violated Sections 10(b) and 20(a) of the Securities Exchange ... 2014, Impax Laboratories, Inc. (the "Company") issued a press ...
(Date:7/29/2014)... 29, 2014 According to the ... Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/Cloud ... & Trends to 2018", published by MarketsandMarkets, analyzes and ... such as North America , ... and the Rest of the World (RoW). ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014  Cannabis Science, Inc. (OTC: ... drug development and related consulting, applauds the Editorial ... a strong position in opposition to current federal ... 2014 publication.  The New York Times also announces ... week exploring the issue called "High Time:  An ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... Corgenix to serve as subcontractor to Battelle for ... related programsDENVER, Jan. 26 Corgenix Medical Corporation ... marketer of diagnostic test kits, has announced a ... and development organization whose business focus includes national ...
... BEIJING, Jan. 26 /PRNewswire-Asia/ -- Sinovac Biotech ... of vaccines in China, today,announced its wholly ... has obtained approval from China,s Ministry of ... developed inactivated animal rabies,vaccine with independent intellectual ...
... Jan. 26 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ... the efficacy portion of its initial Phase 3 clinical,trial ... the acute treatment of migraine. , ... the potential to be,both fast acting and long-lasting, providing ...
Cached Biology Technology:Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 2MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 3
(Date:7/28/2014)... of people in the United States have a circulatory ... can be painful and may even require surgery in ... muscle wasting and, in turn, limb amputation. , At ... (UTHealth) Medical School, scientists tested a non-surgical preventative treatment ... was associated with increased blood circulation. Their proof-of-concept ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the ... of researchers including the labs headed by Professors Neelima ... of Plant Biology. The new genome information may help ... published July 27 in the journal Nature Genetics ... Aachen University in Germany. The UC Davis labs carried ...
(Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... - can get you lost - quick. Tons of genes, tons ... being unknown, tons of database with tons of information... and your ... meaningfull way. Applications are being developped to make it all easier, ... I didn't have time to try it yet, but it seems ...
... approval to Mylan Technologies, Inc., for the first generic ... used to treat patients suffering from severe chronic pain ... to the skin, this patch technology delivers fentanyl, an ... body through the skin providing pain relief for up ...
... and Drug Administration (FDA) has granted approval to Mylan ... Corporation's Duragesic Patch (Fentanyl Transdermal System) used to treat ... managed with alternative analgesics. When applied to the skin, ... that is slowly absorbed into the body through the ...
Cached Biology News:GeneNotes - A novel information management software for biologists 2
... analysis of gene expression) technology ... Expression profiles generated by SAGE ... low-abundance transcripts making it possible ... I-SAGE Kit is designed to ...
Human LAIR2 Biotinylated Affinity Purified PAb...
... mycobacteria in Complete Freund's adjuvant attract macrophages ... which enhances the immuneresponse. For this reason, ... the initial injections; Incomplete Freund's adjuvant is ... in saline) are typically mixed with an ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
Biology Products: